{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,30]],"date-time":"2026-06-30T00:15:06Z","timestamp":1782778506796,"version":"3.54.5"},"reference-count":49,"publisher":"Public Library of Science (PLoS)","issue":"1","license":[{"start":{"date-parts":[[2017,1,20]],"date-time":"2017-01-20T00:00:00Z","timestamp":1484870400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"This study was financially supported by Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology","award":["2016A016"],"award-info":[{"award-number":["2016A016"]}]}],"content-domain":{"domain":["www.plosone.org"],"crossmark-restriction":false},"short-container-title":["PLoS ONE"],"DOI":"10.1371\/journal.pone.0170246","type":"journal-article","created":{"date-parts":[[2017,1,20]],"date-time":"2017-01-20T20:19:59Z","timestamp":1484943599000},"page":"e0170246","update-policy":"https:\/\/doi.org\/10.1371\/journal.pone.corrections_policy","source":"Crossref","is-referenced-by-count":24,"title":["Efficacy and Safety of Everolimus for Maintenance Immunosuppression of Kidney Transplantation: A Meta-Analysis of Randomized Controlled Trials"],"prefix":"10.1371","volume":"12","author":[{"given":"Jinyu","family":"Liu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dong","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Juan","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lan","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chengliang","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kai","family":"Lei","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qiling","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ruxu","family":"You","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"340","published-online":{"date-parts":[[2017,1,20]]},"reference":[{"issue":"3","key":"ref1","doi-asserted-by":"crossref","first-page":"e810","DOI":"10.1097\/MJT.0000000000000150","article-title":"Tacrolimus versus cyclosporine as primary immunosuppressant after renal transplantation: A Meta-Analysis and economics evaluation","volume":"23","author":"JY Liu","year":"2016","journal-title":"Am J Ther"},{"issue":"26","key":"ref2","first-page":"2599","article-title":"Belatacept and Long-Term outcomes in kidney transplantation","volume":"374","author":"LV Riella","year":"2016","journal-title":"N Engl J Med"},{"issue":"Suppl 3","key":"ref3","first-page":"131","article-title":"Kidney disease improving global outcomes (KDIGO) clinical practise guideline for the care of kidney transplantation receipts","volume":"9","year":"2009","journal-title":"American Journal of tansplantation"},{"issue":"10","key":"ref4","doi-asserted-by":"crossref","first-page":"1170","DOI":"10.3390\/ph6101170","article-title":"Safety of immunosuppressive drugs used as maintenance therapy in kidney transplantation: A systematic review and Meta-Analysis","volume":"6","author":"C Almeida","year":"2013","journal-title":"Pharmaceuticals"},{"issue":"4","key":"ref5","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1097\/01.TP.0000128636.70499.6E","article-title":"Calcineurin inhibitor nephrotoxicity: Longitudinal assessment by protocol histology","volume":"78","author":"BJ Nankivell","year":"2004","journal-title":"Transplantation"},{"issue":"8","key":"ref6","doi-asserted-by":"crossref","first-page":"1723","DOI":"10.1097\/TP.0000000000001243","article-title":"Calcineurin inhibitor nephrotoxicity through the lens of longitudinal histology","volume":"100","author":"BJ Nankivell","year":"2016","journal-title":"Transplantation"},{"issue":"3","key":"ref7","doi-asserted-by":"crossref","first-page":"388","DOI":"10.1556\/APhysiol.101.2014.3.13","article-title":"Side effects of the calcineurin inhibitor, such as new-onset diabetes after kidney transplantation","volume":"101","author":"B Borda","year":"2014","journal-title":"Acta Physiologica Hungarica"},{"issue":"4","key":"ref8","doi-asserted-by":"crossref","first-page":"693","DOI":"10.1111\/j.1600-6143.2011.03504.x","article-title":"Chronic calcineurin inhibitor Nephrotoxicity-Lest we forget","volume":"11","author":"JR Chapman","year":"2011","journal-title":"American Journal of Transplantation"},{"issue":"3","key":"ref9","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1016\/j.trre.2011.05.002","article-title":"The influence of immunosuppressive agents on BK virus risk following kidney transplantation, and implications for choice of regimen","volume":"26","author":"B Suwelack","year":"2012","journal-title":"Transplant Rev (Orlando)"},{"issue":"6","key":"ref10","doi-asserted-by":"crossref","first-page":"807","DOI":"10.1517\/17425255.4.6.807","article-title":"Everolimus: An update on the mechanism of action, pharmacokinetics and recent clinical trials","volume":"4","author":"AI Sanchez-Fructuoso","year":"2008","journal-title":"Expert Opin Drug Metab Toxicol"},{"issue":"9","key":"ref11","doi-asserted-by":"crossref","first-page":"1898","DOI":"10.1097\/TP.0000000000001291","article-title":"MTOR inhibition suppresses posttransplant alloantibody production through direct inhibition of alloprimed b cells and sparing of CD8+ Antibody-Suppressing t cells","volume":"100","author":"CL Avila","year":"2016","journal-title":"Transplantation"},{"key":"ref12","doi-asserted-by":"crossref","first-page":"403280","DOI":"10.1155\/2013\/403280","article-title":"Systemic and nonrenal adverse effects occurring in renal transplant patients treated with mTOR inhibitors","volume":"2013","author":"G Zaza","year":"2013","journal-title":"Clin Dev Immunol"},{"issue":"2","key":"ref13","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1111\/j.1399-0012.2010.01232.x","article-title":"MTOR inhibitor-associated dermatologic and mucosal problems","volume":"24","author":"JM Campistol","year":"2010","journal-title":"Clin Transplant"},{"issue":"34","key":"ref14","first-page":"3229","article-title":"Meta-analysis of immunosuppressive therapy with target-of-rapamycin inhibitor instead of calcineurin inhibitor after kidney transplantation operation","volume":"22","author":"W Bin","year":"2011","journal-title":"China Pharmacy"},{"issue":"3","key":"ref15","doi-asserted-by":"crossref","first-page":"621","DOI":"10.1097\/TP.0000000000001006","article-title":"Conversion from calcineurin to mammalian target of rapamycin inhibitors in liver transplantation","volume":"100","author":"TE Glover","year":"2016","journal-title":"Transplantation"},{"issue":"9","key":"ref16","doi-asserted-by":"crossref","first-page":"2106","DOI":"10.1111\/ajt.12795","article-title":"A systematic review of conversion from calcineurin inhibitor to mammalian target of rapamycin inhibitors for maintenance immunosuppression in kidney transplant recipients","volume":"14","author":"WH Lim","year":"2014","journal-title":"Am J Transplant"},{"issue":"12","key":"ref17","doi-asserted-by":"crossref","first-page":"2493","DOI":"10.1681\/ASN.2008111186","article-title":"The role of the mammalian target of rapamycin (mTOR) in renal disease","volume":"20","author":"W Lieberthal","year":"2009","journal-title":"J Am Soc Nephrol"},{"issue":"1","key":"ref18","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/j.trre.2011.10.003","article-title":"MTOR inhibitor-associated proteinuria in kidney transplant recipients","volume":"26","author":"F Diekmann","year":"2012","journal-title":"Transplant Rev (Orlando)"},{"key":"ref19","doi-asserted-by":"crossref","first-page":"d5928","DOI":"10.1136\/bmj.d5928","article-title":"The Cochrane Collaboration's tool for assessing risk of bias in randomised trials","volume":"343","author":"JPT Higgins","year":"2011","journal-title":"Bmj-Brit Med J"},{"key":"ref20","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1186\/2046-4053-3-37","article-title":"Evaluation of the Cochrane Collaboration's tool for assessing the risk of bias in randomized trials: Focus groups, online survey, proposed recommendations and their implementation","volume":"3","author":"J Savovic","year":"2014","journal-title":"Systematic reviews"},{"key":"ref21","doi-asserted-by":"crossref","first-page":"b2700","DOI":"10.1136\/bmj.b2700","article-title":"The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate healthcare interventions: Explanation and elaboration","volume":"339","author":"A Liberati","year":"2009","journal-title":"BMJ"},{"issue":"2","key":"ref22","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1111\/tri.12688","article-title":"CD25 blockade in kidney transplant patients randomized to standard-dose or high-dose basiliximab with cyclosporine, or high-dose basiliximab in a calcineurin inhibitor-free regimen","volume":"29","author":"G Thibault","year":"2016","journal-title":"Transpl Int"},{"issue":"5","key":"ref23","doi-asserted-by":"crossref","first-page":"1303","DOI":"10.1111\/ajt.13132","article-title":"Fibrosis progression according to Epithelial-Mesenchymal transition profile: A randomized trial of everolimus versus CsA","volume":"15","author":"L Rostaing","year":"2015","journal-title":"Am J Transplant"},{"issue":"1","key":"ref24","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1111\/ajt.12952","article-title":"Five-Year outcomes in kidney transplant patients converted from cyclosporine to everolimus: The randomized ZEUS study","volume":"15","author":"K Budde","year":"2015","journal-title":"Am J Transplant"},{"issue":"1","key":"ref25","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1111\/tri.12437","article-title":"Renal function three years after early conversion from a calcineurin inhibitor to everolimus: Results from a randomized trial in kidney transplantation","volume":"28","author":"L Mjornstedt","year":"2015","journal-title":"Transpl Int"},{"issue":"1","key":"ref26","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1007\/s40620-014-0134-4","article-title":"Renal function to 5 years after late conversion of kidney transplant patients to everolimus: A randomized trial","volume":"28","author":"K Budde","year":"2015","journal-title":"J Nephrol"},{"issue":"01","key":"ref27","doi-asserted-by":"crossref","first-page":"11","DOI":"10.5414\/CN108444","article-title":"Renal, efficacy and safety outcomes following late conversion of kidney transplant patients from calcineurin inhibitor therapy to everolimus: The randomized APOLLO study","volume":"83","author":"K Budde","year":"2015","journal-title":"Clin Nephrol"},{"issue":"3","key":"ref28","doi-asserted-by":"crossref","first-page":"302","DOI":"10.1111\/tri.12252","article-title":"A randomized, controlled trial of everolimus-based dual immunosuppression versus standard of care in de novo kidney transplant recipients","volume":"27","author":"SJ Chadban","year":"2014","journal-title":"Transpl Int"},{"issue":"6","key":"ref29","doi-asserted-by":"crossref","first-page":"1528","DOI":"10.1111\/j.1600-6143.2012.03994.x","article-title":"Conversion From Cyclosporine to Everolimus at 4.5 Months Posttransplant: 3-Year Results From the Randomized ZEUS Study","volume":"12","author":"K Budde","year":"2012","journal-title":"Am J Transplant"},{"issue":"10","key":"ref30","doi-asserted-by":"crossref","first-page":"2744","DOI":"10.1111\/j.1600-6143.2012.04162.x","article-title":"Improved renal function after early conversion from a calcineurin inhibitor to everolimus: A randomized trial in kidney transplantation","volume":"12","author":"L Mj\u00f6rnstedt","year":"2012","journal-title":"Am J Transplant"},{"issue":"Suppl 10","key":"ref31","first-page":"S995","article-title":"Efficacy and Safety of Three Different Treatment Regimens in de","volume":"94","author":"W Arns","year":"2012","journal-title":"Transplantation"},{"issue":"4","key":"ref32","doi-asserted-by":"crossref","first-page":"410","DOI":"10.1097\/TP.0b013e318224c12d","article-title":"Conversion of Long-Term kidney transplant recipients from calcineurin inhibitor therapy to everolimus: ARandomized, multicenter, 24-Month study","volume":"92","author":"LRDS Hallvard Holdaas","year":"2011","journal-title":"Transplantation"},{"issue":"9768","key":"ref33","doi-asserted-by":"crossref","first-page":"837","DOI":"10.1016\/S0140-6736(10)62318-5","article-title":"Everolimus-based, calcineurin-inhibitor-free regimen in recipients of de-novo kidney transplants: An open-label, randomised, controlled trial","volume":"377","author":"K Budde","year":"2011","journal-title":"The Lancet"},{"issue":"3","key":"ref34","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1097\/TP.0b013e3181af1df6","article-title":"Minimization of maintenance immunosuppression early after renal transplantation: An interim analysis","volume":"88","author":"FJ Bemelman","year":"2009","journal-title":"Transplantation"},{"issue":"11","key":"ref35","doi-asserted-by":"crossref","first-page":"2213","DOI":"10.1097\/HJH.0b013e32830ef940","article-title":"Switch of immunosuppression from cyclosporine a to everolimus: Impact on pulse wave velocity in stable de-novo renal allograft recipients","volume":"26","author":"J Seckinger","year":"2008","journal-title":"J Hypertens"},{"issue":"2","key":"ref36","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1097\/TP.0b013e3181ac8cdd","article-title":"Contrast enhanced sonography shows superior microvascular renal allograft perfusion in patients switched from cyclosporine a to everolimus","volume":"88","author":"LP Kihm","year":"2009","journal-title":"Transplantation"},{"issue":"11","key":"ref37","doi-asserted-by":"crossref","first-page":"3750","DOI":"10.1093\/ndt\/gfr091","article-title":"Clinical assessment and determinants of chronic allograft nephropathy in maintenance renal transplant patients","volume":"26","author":"JM Grinyo","year":"2011","journal-title":"Nephrology Dialysis Transplantation"},{"issue":"Suppl 99","key":"ref38","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1111\/j.1523-1755.2005.09920.x","article-title":"Longitudinal analysis of chronic allograft nephropathy: Clinicopathologic correlations","volume":"68","author":"JR CHAPMAN","year":"2005","journal-title":"Kidney International"},{"issue":"2","key":"ref39","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1111\/j.1399-0012.2009.01043.x","article-title":"Proteinuria >0.5 g\/d, a prevalent prognostic factor for patient and graft survival in kidney transplantation","volume":"24","author":"F Cantarovich","year":"2010","journal-title":"Clinical Transplantation"},{"issue":"6","key":"ref40","article-title":"Very low-grade proteinuria at 3 months posttransplantation is an earlier marker of graft survival","volume":"41","author":"CA Sancho","year":"2009","journal-title":"Transplant Proc"},{"issue":"9","key":"ref41","doi-asserted-by":"crossref","first-page":"2281","DOI":"10.1111\/j.1600-6143.2005.01020.x","article-title":"Early low-grade proteinuria: Causes, short-term evolution and long-term consequences in renal transplantation","volume":"5","author":"JM Halimi","year":"2005","journal-title":"American Journal of Transplantation"},{"issue":"9","key":"ref42","doi-asserted-by":"crossref","first-page":"1234","DOI":"10.1097\/01.tp.0000219703.39149.85","article-title":"Target of rapamycin inhibitors (Sirolimus and everolimus) for primary immunosuppression of kidney transplant recipients: A systematic review and Meta-Analysis of randomized trials","volume":"81","author":"AC Webster","year":"2006","journal-title":"Transplantation"},{"issue":"4","key":"ref43","doi-asserted-by":"crossref","first-page":"398","DOI":"10.1097\/TP.0b013e31823ffd0e","article-title":"Everolimus as primary immunosuppression in kidney transplantation: Experience in conversion from calcineurin inhibitors","volume":"93","author":"AI Sanchez-Fructuoso","year":"2012","journal-title":"Transplantation"},{"issue":"7","key":"ref44","doi-asserted-by":"crossref","first-page":"1855","DOI":"10.1111\/j.1600-6143.2012.04049.x","article-title":"A randomized, controlled study to assess the conversion from calcineurin-inhibitors to everolimus after liver transplantation\u2014PROTECT","volume":"12","author":"L Fischer","year":"2012","journal-title":"Am J Transplant"},{"issue":"4","key":"ref45","doi-asserted-by":"crossref","first-page":"1297","DOI":"10.1016\/j.transproceed.2010.03.120","article-title":"De novo Everolimus-Based therapy in renal transplant recipients: Effect on proteinuria and renal prognosis","volume":"42","author":"G Loriga","year":"2010","journal-title":"Transpl P"},{"issue":"8","key":"ref46","doi-asserted-by":"crossref","first-page":"1360","DOI":"10.1093\/ndt\/gfw088","article-title":"Immunosuppression with mammalian target of rapamycin inhibitor and incidence of post-transplant cancer in kidney transplant recipients","volume":"31","author":"G Opelz","year":"2016","journal-title":"Nephrol Dial Transplant"},{"issue":"Suppl 3","key":"ref47","doi-asserted-by":"crossref","first-page":"S57","DOI":"10.1111\/nep.12247","article-title":"De novo proteinuria with pathological evidence of glomerulonephritis after everolimus induction","volume":"19","author":"M Miura","year":"2014","journal-title":"Nephrology"},{"key":"ref48","article-title":"Mammalian target of rapamycin inhibitors and clinical outcomes in adult kidney transplant recipients","author":"SV Badve","year":"2016","journal-title":"Clin J Am Soc Nephrol"},{"issue":"11","key":"ref49","doi-asserted-by":"crossref","first-page":"1653","DOI":"10.1097\/01.TP.0000144181.47045.FE","article-title":"A randomized controlled trial of cyclosporine withdrawal in renal-transplant recipients: 15-Year results","volume":"78","author":"MP Gallagher","year":"2004","journal-title":"Transplantation"}],"container-title":["PLOS ONE"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/dx.plos.org\/10.1371\/journal.pone.0170246","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2018,10,22]],"date-time":"2018-10-22T14:06:41Z","timestamp":1540217201000},"score":1,"resource":{"primary":{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0170246"}},"subtitle":[],"editor":[{"given":"Stanislaw","family":"Stepkowski","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]}],"short-title":[],"issued":{"date-parts":[[2017,1,20]]},"references-count":49,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2017,1,20]]}},"URL":"https:\/\/doi.org\/10.1371\/journal.pone.0170246","relation":{},"ISSN":["1932-6203"],"issn-type":[{"value":"1932-6203","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,1,20]]}}}